A lthough epidemiological evidence demonstrates an association between cardiovascular (CV) disease and impaired lung function that is independent of smoking, the mechanisms involved remain unclear. Aortic stiffness has emerged as a major independent predictor of CV risk in a number of population-based studies 1 and an inverse association of lung function parameters and aortic stiffness using aortic pulse wave velocity (aPWV) has been described in over 800 men from the Caerphilly Prospective Study. 2 Aortic stiffness has also been studied in specific chronic lung disease cohorts and was increased in patients with chronic obstructive pulmonary disease (COPD). 3 The population-based study by Jankowich et al. reported in the current issue of the Journal 4 extends previous findings to examine the relationship between lung function and arterial stiffness in a large well defined cohort of subjects, 13,090 men and women, from the NHANES study. The authors examined the relationship between pulse pressure (PP), a surrogate marker of arterial stiffness, and lung function assessed by the spirometric measurement of forced expiratory volume in one second (FEV 1 ) and demonstrated a significant relationship in those over 40 years old. However as yet, they have reported no CV outcome data. This is important because due to PP amplification, 1 brachial PP as assessed in the current study does not accurately reflect central PP, the pressure that the heart and vital organs are actually exposed to. Moreover, central PP is a better predictor of end-organ damage and CV outcome than brachial PP. 1 Nonetheless brachial PP has been shown to be an important predictor of outcome especially in older individuals 5 and the numbers in the current study are impressive.
Clinical relevance, especially to the individual patient, of the modest increase in brachial PP for each standard deviation (approximates to 1.3 l) drop in FEV 1 should be considered with caution given the magnitude of the comparative crosssectional lung function to cause this. However, it is readily measurable in clinic and supported by aPWV data.
In addition, although the study by Jankowich et al. 4 provides further confirmation of the link between impaired lung function and arterial stiffness, it provides little insight into potential mechanisms. This is important as a better understanding of such mechanisms should lead to therapeutic strategies designed to decrease CV mortality and morbidity in subjects with such lung function impairment in chronic lung disease such as COPD. Certain disease-specific mechanisms, reverse causality or a third common factor need to be explored. Systemic inflammation known to be increased in a number of chronic lung diseases would appear an obvious candidate, but no evidence to support this or indeed involvement of conventional risk factors such as serum cholesterol is provided by the current study. This is perhaps unsurprising as a recent systematic analysis of published data suggested that conventional risk factors other than age and blood pressure had minimal effect on aPWV. 6 In summary, the study by Jankowich et al. 4 provides strong evidence to support a link between lung function and arterial stiffness but little insight into possible mechanisms. A better understanding of the underlying mechanisms for this association may result in targeted therapies designed to decrease arterial stiffness and hence CV events. This remains a stiff challenge.
